- Home
- EVF vs TCRX Comparison
EVF vs TCRX Comparison
Compare EVF & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVF
- TCRX
- Stock Information
- Founded
- EVF 1998
- TCRX 2018
- Country
- EVF United States
- TCRX United States
- Employees
- EVF N/A
- TCRX N/A
- Industry
- EVF Investment Managers
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- EVF Finance
- TCRX Health Care
- Exchange
- EVF Nasdaq
- TCRX Nasdaq
- Market Cap
- EVF 102.2M
- TCRX 90.5M
- IPO Year
- EVF N/A
- TCRX 2021
- Fundamental
- Price
- EVF $5.69
- TCRX $1.33
- Analyst Decision
- EVF
- TCRX Strong Buy
- Analyst Count
- EVF 0
- TCRX 7
- Target Price
- EVF N/A
- TCRX $9.86
- AVG Volume (30 Days)
- EVF 93.3K
- TCRX 381.4K
- Earning Date
- EVF 01-01-0001
- TCRX 05-06-2025
- Dividend Yield
- EVF 10.68%
- TCRX N/A
- EPS Growth
- EVF N/A
- TCRX N/A
- EPS
- EVF 0.94
- TCRX N/A
- Revenue
- EVF N/A
- TCRX $4,421,000.00
- Revenue This Year
- EVF N/A
- TCRX $47.30
- Revenue Next Year
- EVF N/A
- TCRX $74.30
- P/E Ratio
- EVF $6.74
- TCRX N/A
- Revenue Growth
- EVF N/A
- TCRX N/A
- 52 Week Low
- EVF $5.20
- TCRX $1.02
- 52 Week High
- EVF $6.84
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- EVF 54.81
- TCRX 42.34
- Support Level
- EVF $5.60
- TCRX $1.32
- Resistance Level
- EVF $5.73
- TCRX $1.65
- Average True Range (ATR)
- EVF 0.07
- TCRX 0.12
- MACD
- EVF 0.02
- TCRX -0.02
- Stochastic Oscillator
- EVF 86.67
- TCRX 13.04
About EVF Eaton Vance Senior Income Trust
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.